LifeStance Health Group, Inc. (LFST) – What Are Analysts Thinking About This Stock?

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $13.12.

LFST has been the subject of several research analyst reports. BTIG Research upped their target price on shares of LifeStance Health Group from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Barclays lifted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. boosted their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Finally, Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th.

LifeStance Health Group Stock Up 0.8%

LFST stock opened at $13.37 on Friday. The company has a fifty day simple moving average of $12.52 and a 200 day simple moving average of $9.40. LifeStance Health Group has a 1 year low of $4.79 and a 1 year high of $13.76. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The firm has a market cap of $5.11 billion, a PE ratio of 102.85 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. The company’s revenue was up 26.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) earnings per share. Sell-side analysts anticipate that LifeStance Health Group will post 0.16 EPS for the current fiscal year.

Insider Activity

In other news, COO Lisa Miller sold 47,912 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO Vukasin Paunovich sold 42,067 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total value of $541,402.29. Following the transaction, the chief technology officer directly owned 205,379 shares in the company, valued at $2,643,227.73. This trade represents a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 13,777,580 shares of company stock valued at $146,433,781. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently modified their holdings of LFST. BlackRock Inc. bought a new position in shares of LifeStance Health Group in the 2nd quarter worth $389,293,000. Wellington Management Group LLP acquired a new position in LifeStance Health Group in the second quarter valued at about $30,881,000. Jennison Associates LLC boosted its holdings in LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after buying an additional 2,843,388 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after buying an additional 1,461,215 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of LifeStance Health Group during the 2nd quarter worth about $14,987,000. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.